ClinicalTrials.gg
CompletedNCT02573012Updated Nov 1, 2019Results posted

Study to Compare the Efficacy of Tocilizumab With or Without Glucocorticoid Discontinuation in Rheumatoid Arthritis Participants

A Phase 4 interventional study of Placebo matched to prednisone and Prednisone in Rheumatoid Arthritis, sponsored by Hoffmann-La Roche. Completed at 39 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-11-01.

Sponsored by Hoffmann-La Roche · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
314
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 110 studies testing tocilizumab in Arthritis, Rheumatoid — 5 open to participants now, 5 under way, none of them phase 3. tocilizumab · Arthritis, Rheumatoid.

Enrollment
20th of 110
314 · median 97
Started
2016
with 3 others
Phase 4
32 of 110
2 open now
Registered
89th of 110
by date
Lead sponsor
67 of 110
Hoffmann-La Roche

Among the 110 studies testing tocilizumab in Arthritis, Rheumatoid, this one is the 20th largest by enrollment, is one of 4 that started in 2016, is one of 32 in phase 4, and was the 89th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

5 of the 110 studies testing tocilizumab in Arthritis, Rheumatoid are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About tocilizumab

tocilizumab: first FDA approval 2010 (ACTEMRA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 110 studies testing tocilizumab in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

This Phase IIIb/IV, two-arm, randomized, double-blind, placebo-controlled, parallel-group, international, multicenter trial compares the change in disease activity (as assessed by Disease Activity Score in 28 joints [DAS28] erythrocyte sedimentation rate [ESR]) from randomization to Week 24 post-randomization, in participants with stable low disease activity [LDA] (DAS28 ESR score less than or equal to [\<=] 3.2) who receive tocilizumab, and have been randomized to either continue or taper prednisone in a double-blinded fashion.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Tocilizumab-experienced participants:

  • Comply with the requirements of the study protocol (including treatment on an outpatient basis)
  • Rheumatoid arthritis (RA) of greater than or equal to (>=) 6 months duration diagnosed according to the revised 1987 American College of Rheumatology (ACR) criteria or 2010 ACR / European League Against Rheumatism (EULAR) criteria
  • Have received tocilizumab either subcutaneous (162 milligram [mg] once in a week) or intravenously (8 milligram per kilogram [mg/kg] once every 4 weeks) for the treatment of RA for at least 24 weeks prior to randomization
  • Have received 5 - 15 milligrams per day [mg/day] of (prednisone or equivalent) for the treatment of RA for at least 20 weeks prior to screening
  • Currently receiving 5 mg/day of prednisone
  • Have attained and maintained LDA (DAS28 ESR score \<=3.2) or remission (DAS28 ESR score less than [\<] 2.6) for at least 4 weeks prior to randomization

Tocilizumab-naïve participants:

  • Comply with the requirements of the study protocol (including treatment on an outpatient basis)
  • RA of >=6 months duration diagnosed according to the revised 1987 ACR criteria or 2010 ACR / EULAR criteria
  • Have active RA (defined as DAS28 ESR score greater than [>] 3.2)
  • Are considered by the investigator as inadequate responders to conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) or biologic disease-modifying anti-rheumatic drugs (bDMARDs)
  • Are receiving 5 - 15 mg/day prednisone (or equivalent) for the treatment of RA

Exclusion criteria

Exclusion Criteria:

General

  • Major surgery (including joint surgery) within 8 weeks prior to screening, or planned major surgery during the study and up to 6 months after randomization
  • Pregnant women or nursing (breastfeeding) mothers
  • In females of , a positive serum pregnancy test at screening
  • Females of childbearing potential unwilling or unable to use a reliable means of (for example, physical barrier [participant or partner], contraceptive pill or patch, spermicide and barrier, or intrauterine device) during study treatment and for a minimum of 3 months after the last dose of tocilizumab
  • Body weight of >=150 kilogram (kg)
  • Lack of peripheral venous access

Disease-related

  • RA of functional Class 4, as defined by the ACR Classification of Functional Status in Rheumatoid Arthritis
  • Rheumatic disease other than RA, including systemic lupus erythematosus, mixed connective tissue disease, scleroderma, polymyositis, or significant systemic involvement secondary to RA (for example, vasculitis, pulmonary fibrosis, or Felty syndrome). Secondary Sjögren syndrome with RA may be allowed per the discretion of the investigator
  • Diagnosed with juvenile idiopathic arthritis or juvenile RA and/or RA before the age of 16 years
  • Prior or current inflammatory joint disease other than RA (for example, gout, Lyme disease, sero-negative spondyloarthropathy, including reactive arthritis, psoriatic arthritis, arthropathy of inflammatory bowel disease), or prior or current joint infections
  • Previous history of primary or secondary adrenal insufficiency

Previous or Concomitant Prohibited Therapy

  • Treatment with any agent within 4 weeks (or 5 half-lives of the investigational drug, whichever is longer) of screening
  • Previous treatment with any cell-depleting therapies, including investigational agents or approved therapies (for example, CAMPATH, anti-CD4, anti-CD5, anti-CD3, anti-CD19, anti-CD20)
  • Treatment with intravenous gamma globulin, plasmapheresis or Prosorba column within 6 months of screening
  • Intraarticular (IA) or parenteral for the treatment of RA within 4 weeks prior to screening
  • Previous treatment with glucocorticoids for conditions other than RA, at any dose and in any formulation used continuously for >1 week, during the last 1 year prior to screening. Topical glucocorticoid creams or ointments for the treatment of skin conditions (for example eczema) are allowed
  • Immunization with a live/attenuated vaccine within 30 days prior to screening. Participants must agree not to take (including seasonal nasal flu vaccine, varicella vaccine for shingles or chickenpox, vaccines for measles, mumps or rubella without or with varicella [MMR or MMRV], oral polio vaccine and vaccines for yellow fever), within 30 days before the Screening Visit, throughout the duration of the trial and for 60 days following the last dose of study drug
  • Any previous treatment with alkylating agents such as chlorambucil or with total lymphoid irradiation

Laboratory Exclusion Criteria

  • Inadequate haematological, renal and liver function
  • Positive surface antigen or antibody Previous or Concomitant Conditions
  • History of severe allergic or anaphylactic reactions to human, humanized, or murine monoclonal antibodies
  • Evidence of current serious uncontrolled cardiovascular (including uncontrolled hyperlipidemia), nervous system, pulmonary (including obstructive pulmonary disease), renal, hepatic, endocrine (including uncontrolled diabetes mellitus) or gastrointestinal (GI) disease
  • Current liver disease as determined by the investigator
  • History of diverticulitis, peptic ulcer disease, diverticulosis requiring antibiotic treatment, or chronic ulcerative lower GI disease such as Crohn's disease, ulcerative colitis, or other symptomatic lower gastrointestinal conditions that might predispose to perforations
  • Known active current or history of recurrent bacterial, viral, fungal, mycobacterial, or other opportunistic infections (including, but not limited to, tuberculosis [TB] and atypical mycobacterial disease, hepatitis B and C, Epstein-Barr virus, cytomegalovirus and herpes zoster, but excluding fungal infections of nail beds)
  • Neuropathies or other conditions that might interfere with pain evaluation unless related to primary disease under investigation
  • Any major episode of infection requiring hospitalization or treatment with intravenous antibiotics within 4 weeks of screening or oral antibiotics within 2 weeks prior to screening
  • Active TB requiring treatment within the previous 3 years (participants previously treated for TB with no recurrence within 3 years are permitted). All Track tocilizumab-naïve participants must be screened for latent TB and if positive, should be treated following local practice guidelines prior to initiating tocilizumab
  • History of or currently active, primary or secondary immunodeficiency
  • Evidence of active malignant disease, diagnosed within the previous 10 years (including haematological malignancies and solid tumours, except basal and squamous cell carcinoma of the skin or carcinoma in situ of the cervix uteri that was excised and cured), or breast cancer diagnosed within the previous 20 years
  • History of alcohol, drug or chemical abuse within 1 year prior to screening
  • Pre-existing central nervous system (CNS) demyelination or seizure disorders
  • Any medical or psychological condition that in the opinion of the principal investigator would interfere with safe completion of the trial
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
314 participants (actual)

Study arms

  • Experimental
    Tocilizumab+prednisone (constant dose)

    Participants will receive tocilizumab at a dose of 162 milligram (mg) once a week subcutaneously; and prednisone at a dose of 5 milligram per day (mg/day) or matching placebo orally for 24 weeks.

    Drug: Placebo matched to prednisone · Drug: Prednisone · Biological: Tocilizumab

  • Experimental
    Tocilizumab+prednisone (tapering dose)

    Participants will receive tocilizumab at a dose of 162 milligram (mg) once a week subcutaneously; and prednisone at a dose of 5 milligram per day (mg/day) with 1 mg decrements every 4 weeks or matching placebo orally for 24 weeks.

    Drug: Placebo matched to prednisone · Drug: Prednisone · Biological: Tocilizumab

Interventions

  • DrugPlacebo matched to prednisone

    Participants will receive placebo matched to prednisone orally for 24 weeks.

  • Participants will receive prednisone either at a constant dose of 5 mg/day, or 5 mg/day with 1 mg decrements every 4 weeks orally for 24 weeks.

  • BiologicalTocilizumab

    Participants will receive tocilizumab at a dose of 162 mg once a week subcutaneously for 24 weeks.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Disease Activity Score in 28 Joints - Erythrocyte Sedimentation Rate (DAS28-ESR) at Week 24 Post-randomization

    The DAS28 is a combined index for measuring disease activity in rheumatic arthritis (RA) and includes swollen and tender joint count, erythrocyte sedimentation rate (ESR), and general health (GH) status. The index is calculated with the following formula: DAS28 = (0.56 × √(TJC28)) + (0.28 × √(SJC28)) + (0.7 × log(ESR)) + (0.014 × GH), where TJC28 = tender joint count and SJC28 = swollen joint count, each on 28 joints. GH = a patient's global assessment of disease activity in the previous 24 hours on a 100-millimeter (mm) visual analog scale (left end = no disease activity \[symptom-free and no arthritis symptoms\], right end = maximum disease activity \[maximum arthritis disease activity\]). When ESR equaled 0 mm/hr, it was set to 1 mm/hr. The DAS28 scale ranges from 0 to 10, where higher scores represent higher disease activity. A positive change in score indicates worsening, and a negative change indicates improvement.

    Time frame: Baseline to Week 24

Secondary outcomes

  1. Treatment Success

    Treatment success was defined as the percentage of participants with stable low disease activity (LDA) (DAS28-ESR score ≤ 3.2) at Week 24 post-randomization, who did not suffer a flare due to RA and who showed no confirmed adrenal insufficiency that required replacement therapy. DAS28 has the following standardized cut-offs for disease activity and remission: DAS28 \> 5.1 = high disease activity; DAS28 between 3.2 and 5.1 = moderate disease activity; DAS28 ≤ 3.2 = low disease activity; DAS28 ≤ 2.6 = remission.

    Time frame: Week 24

  2. Change From Baseline in Clinical Disease Activity Index (CDAI) at Week 24

    Clinical Disease Activity Index (CDAI) is an index for measuring disease activity in rheumatoid arthritis (RA). The index is calculated using the following formula: CDAI = number of swollen joints using the 28-joint count (SJC28) + number of tender joints using the 28-joint count (TJC28) + patient global assessment of disease (PGA) based on 10 centimeter (cm) visual analog scale (VAS) + physician global assessment of disease (PhGA) based on 10 cm VAS. VAS assessments involved a 100 mm horizontal scale from 0 (no disease activity) to 10 (maximum disease activity). Total CDAI scores range from 0 to 76, with higher scores indicating increased disease activity. A positive change in score indicates worsening, and a negative change indicates improvement.

    Time frame: Baseline and Week 24

  3. Percentage of Participants With >=1 Flare

    Percentage of participants with \>=1 flare

    Time frame: 24 weeks

  4. Time to First RA Flare

    The mean time of onset for the first RA flare since randomization.

    Time frame: Randomization to 24 weeks

  5. Percentage of Visits With RA Flares

    Time frame: Randomization to 24 weeks

  6. Percentage of Participants With >=1 Administration of Flare Rescue Medication

    The proportion of participants with at least one administration of RA flare rescue medication.

    Time frame: Randomization to 24 weeks

  7. Time to First Administration of Flare Rescue Medication

    Time of onset of first administration of RA flare rescue medication since randomization date

    Time frame: Randomization to 24 weeks

  8. Number of Administrations of Flare Rescue Medication

    Proportion of participants who received courses of RA flare rescue medication by number of courses received.

    Time frame: Randomization to 24 weeks

  9. Cumulative Prednisone Exposure (Dose)

    In Post-randomization prednisone arm, Cumulative dose = (number of capsules taken during week 1 to 4 \* 1 mg) + (3/4 \* number of capsules taken during week 5 to 8 \* 1 mg) + (1/2 \* number of capsules taken during week 9 to 12 \* 1 mg) + (1/4 \* number of capsules taken during week 13 to 16 \* 1 mg). In continued arm, cumulative dose = (1/4 \* number of capsule taken \* 5 mg). Cumulative prednisone dose is defined as cumulative blinded prednisone + cumulative flare rescue prednisone.

    Time frame: Randomization to 24 weeks

  10. Percentage of Participants Who Maintain LDA (DAS28 ESR Score <=3.2) or Remission (DAS28 ESR Score <2.6) and the Percentage of Participants Who Maintain the Baseline Disease Activity Level

    The proportion of participants who maintained LDA and the proportion of participants who maintained the baseline disease activity level at Week 24. LDA was defined as DAS28 ESR score \<= 3.2. Remission was defined as DAS28 ESR score \<= 2.6. Participants who maintained the baseline activity was defined as DAS28-ESR at Week 24 \<= DAS28-ESR at baseline.

    Time frame: Randomization to Week 24

  11. Percentage of Participants Who Permanently Discontinue Study Treatment Due to Insufficient Flare Control

    Percentage of participants who permanently discontinue study treatment due to insufficient flare control

    Time frame: 24 weeks

  12. Changes From Baseline in American College of Rheumatology (ACR) Core Set Components at Week 24: Swollen 66 Joint Counts

    Count of swollen joints based upon 66 assessed joints.

    Time frame: Baseline to Week 24

  13. Changes From Baseline in American College of Rheumatology (ACR) Core Set Components at Week 24: Tender 68 Joint Counts

    Count of tender joints based on 68 assessed joints.

    Time frame: Baseline to Week 24

  14. Changes From Baseline in American College of Rheumatology (ACR) Core Set Components at Week 24: Patient's Assessment of Pain

    The ACR patient's assessment of pain is scored on a visual analog scale (VAS) from 0 (no pain) to 100 mm (unbearable pain). A positive change in score indicates worsening, and a negative change indicates improvement.

    Time frame: Baseline to Week 24

  15. Changes From Baseline in American College of Rheumatology (ACR) Core Set Components at Week 24: Patient's Global Assessment of Disease Activity

    The ACR patient's global assessment of disease activity is scored on a visual analog scale (VAS) from 0 (symptom-free and no arthritis symptoms) to 100 mm (maximum arthritis disease activity). A positive change in score indicates worsening, and a negative change indicates improvement.

    Time frame: Baseline to Week 24

  16. Changes From Baseline in American College of Rheumatology (ACR) Core Set Components at Week 24: Physician's Global Assessment of Disease Activity

    The ACR physician's global assessment of disease activity is scored on a visual analog scale (VAS) from 0 (symptom-free and no arthritis symptoms) to 100 mm (maximum arthritis disease activity). A positive change in score indicates worsening, and a negative change indicates improvement.

    Time frame: Baseline to Week 24

  17. Changes From Baseline in American College of Rheumatology (ACR) Core Set Components at Week 24: Health Assessment Questionnaire-Disability Index (HAQ-DI)

    A measure of self-perceived disability containing 20 questions in eight categories and including additional section about aid from other people and devices needed to correct the disabilities. Scores range from 0 to 3, with higher scores indicating worse disability.

    Time frame: Baseline to Week 24

  18. Changes From Baseline in American College of Rheumatology (ACR) Core Set Components at Week 24: High Sensitivity C-Reactive Protein (hsCRP)

    Change from baseline in the acute phase reactant hsCRP

    Time frame: Baseline to Week 24

  19. Changes From Baseline in American College of Rheumatology (ACR) Core Set Components at Week 24: Erythrocyte Sedimentation Rate (ESR)

    Change from baseline in the acute phase reactant ESR

    Time frame: Baseline to Week 24

  20. Changes From Baseline in Rheumatoid Arthritis Impact of Disease (RAID) Final Score

    The RAID is a participant-completed questionnaire specific for RA consisting of a 0-10 rating for pain, functional disability, fatigue, sleep, physical well-being, emotional well-being and coping. Scores are weighted to produce a final numerical result. A positive change in score indicates worsening, and a negative change indicates improvement.

    Time frame: Baseline and Week 24

  21. Changes From Baseline in Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI:SHP) Score

    The WPAI:SHP is a 6-item questionnaire to measure performance impairment of work and regular daily activity and yields 4 types of scores: work time missed (absenteeism), impairment while working (presenteeism or reduced on-the-job effectiveness), overall work impairment (WI) (work productivity loss or absenteeism plus presenteeism) and activity impairment (daily activity impairment). Total score and each score range from 0 (not affected/no impairment) to 100 (completely affected/impaired). Higher scores indicate greater impairment and less productivity. A positive change in score indicates impairment, and a negative change indicates improvement.

    Time frame: Baseline and Week 24

  22. Change From Baseline in Simplified Disease Activity Index (SDAI) at Week 24

    The SDAI is the numerical sum of 5 outcome parameters: tender and swollen joint count based on a 28-joint assessment, patient and physician global assessment of disease activity according to 100-mm visual analog scale (VAS) and level of C-reactive protein in milligrams per deciliter (mg/dL, normal \<1 mg/dl). The total SDAI score range is 0-86, where higher scores indicate increased disease activity. A positive change in score indicates worsening, and a negative change indicates improvement.

    Time frame: Randomization to Week 24

07

Results

Posted Jul 24, 2019

Participant flow

Participant flow — Overall Study
MilestoneTocilizumab+Prednisone (Tapering Dose)Tocilizumab+Prednisone (Constant Dose)
Started131128
Completed116113
Not completed1515
Withdrew: Adverse event55
Withdrew: Lack of efficacy54
Withdrew: Non-compliance12
Withdrew: Withdrawal by subject22
Withdrew: Study ended per protocol10
Withdrew: Physician decision12

Outcome measures

PrimaryChange From Baseline in Disease Activity Score in 28 Joints - Erythrocyte Sedimentation Rate (DAS28-ESR) at Week 24 Post-randomization

The DAS28 is a combined index for measuring disease activity in rheumatic arthritis (RA) and includes swollen and tender joint count, erythrocyte sedimentation rate (ESR), and general health (GH) status. The index is calculated with the following formula: DAS28 = (0.56 × √(TJC28)) + (0.28 × √(SJC28)) + (0.7 × log(ESR)) + (0.014 × GH), where TJC28 = tender joint count and SJC28 = swollen joint count, each on 28 joints. GH = a patient's global assessment of disease activity in the previous 24 hours on a 100-millimeter (mm) visual analog scale (left end = no disease activity \[symptom-free and no arthritis symptoms\], right end = maximum disease activity \[maximum arthritis disease activity\]). When ESR equaled 0 mm/hr, it was set to 1 mm/hr. The DAS28 scale ranges from 0 to 10, where higher scores represent higher disease activity. A positive change in score indicates worsening, and a negative change indicates improvement.

Time frame:
Baseline to Week 24
Reported as:
Least squares mean · Score on a scale
Change From Baseline in Disease Activity Score in 28 Joints - Erythrocyte Sedimentation Rate (DAS28-ESR) at Week 24 Post-randomization
Score on a scaleTocilizumab+Prednisone (Tapering Dose)Tocilizumab+Prednisone (Constant Dose)
Change From Baseline in Disease Activity Score in 28 Joints - Erythrocyte Sedimentation Rate (DAS28-ESR) at Week 24 Post-randomization0.538 (0.346 to 0.729)-0.075 (-0.271 to 0.121)
Statistical analysis
  • Tocilizumab+Prednisone (Tapering Dose) vs Tocilizumab+Prednisone (Constant Dose) · ANCOVA · p = 0.001 · Least square means: 0.613 · 95% CI 0.346 to 0.879
SecondaryTreatment Success

Treatment success was defined as the percentage of participants with stable low disease activity (LDA) (DAS28-ESR score ≤ 3.2) at Week 24 post-randomization, who did not suffer a flare due to RA and who showed no confirmed adrenal insufficiency that required replacement therapy. DAS28 has the following standardized cut-offs for disease activity and remission: DAS28 \> 5.1 = high disease activity; DAS28 between 3.2 and 5.1 = moderate disease activity; DAS28 ≤ 3.2 = low disease activity; DAS28 ≤ 2.6 = remission.

Time frame:
Week 24
Reported as:
Number · Percentage of Participants
Treatment Success
Percentage of ParticipantsTocilizumab+Prednisone (Tapering Dose)Tocilizumab+Prednisone (Constant Dose)
Treatment Success64.9 (56.1 to 73.0)77.3 (69.1 to 84.3)
Statistical analysis
  • Tocilizumab+Prednisone (Tapering Dose) vs Tocilizumab+Prednisone (Constant Dose) · Regression, Logistic · p = 0.018 · Odds ratio (or): 0.50 · 95% CI 0.285 to 0.889
  • Tocilizumab+Prednisone (Tapering Dose) vs Tocilizumab+Prednisone (Constant Dose) · Cochran-Mantel-Haenszel · p = 0.021 · Relative risk: 0.833 · 95% CI 0.714 to 0.972
SecondaryChange From Baseline in Clinical Disease Activity Index (CDAI) at Week 24

Clinical Disease Activity Index (CDAI) is an index for measuring disease activity in rheumatoid arthritis (RA). The index is calculated using the following formula: CDAI = number of swollen joints using the 28-joint count (SJC28) + number of tender joints using the 28-joint count (TJC28) + patient global assessment of disease (PGA) based on 10 centimeter (cm) visual analog scale (VAS) + physician global assessment of disease (PhGA) based on 10 cm VAS. VAS assessments involved a 100 mm horizontal scale from 0 (no disease activity) to 10 (maximum disease activity). Total CDAI scores range from 0 to 76, with higher scores indicating increased disease activity. A positive change in score indicates worsening, and a negative change indicates improvement.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · Score on a scale
Change From Baseline in Clinical Disease Activity Index (CDAI) at Week 24
Score on a scaleTocilizumab+Prednisone (Tapering Dose)Tocilizumab+Prednisone (Constant Dose)
Change From Baseline in Clinical Disease Activity Index (CDAI) at Week 242.663 (1.454 to 3.872)0.321 (-0.914 to 1.556)
Statistical analysis
  • Tocilizumab+Prednisone (Tapering Dose) vs Tocilizumab+Prednisone (Constant Dose) · ANCOVA · p = 0.006 · Least square mean: 2.342 · 95% CI 0.661 to 4.023
SecondaryPercentage of Participants With >=1 Flare

Percentage of participants with \>=1 flare

Time frame:
24 weeks
Reported as:
Number · Percentage of Participants
Percentage of Participants With >=1 Flare
Percentage of ParticipantsTocilizumab+Prednisone (Tapering Dose)Tocilizumab+Prednisone (Constant Dose)
Percentage of Participants With >=1 Flare26.010.9
SecondaryTime to First RA Flare

The mean time of onset for the first RA flare since randomization.

Time frame:
Randomization to 24 weeks
Reported as:
Mean · Weeks
Time to First RA Flare
WeeksTocilizumab+Prednisone (Tapering Dose)Tocilizumab+Prednisone (Constant Dose)
Time to First RA Flare15.64 ± 7.1312.11 ± 7.96
SecondaryPercentage of Visits With RA Flares
Time frame:
Randomization to 24 weeks
Reported as:
Number · Percentage of visits with flares
Percentage of Visits With RA Flares
Percentage of visits with flaresTocilizumab+Prednisone (Tapering Dose)Tocilizumab+Prednisone (Constant Dose)
1 Visit16.07.0
2 Visits6.93.9
3 Visits2.30
>3 Visits0.80
SecondaryPercentage of Participants With >=1 Administration of Flare Rescue Medication

The proportion of participants with at least one administration of RA flare rescue medication.

Time frame:
Randomization to 24 weeks
Reported as:
Number · Percentage of Participants
Percentage of Participants With >=1 Administration of Flare Rescue Medication
Percentage of ParticipantsTocilizumab+Prednisone (Tapering Dose)Tocilizumab+Prednisone (Constant Dose)
Percentage of Participants With >=1 Administration of Flare Rescue Medication20.66.3
SecondaryTime to First Administration of Flare Rescue Medication

Time of onset of first administration of RA flare rescue medication since randomization date

Time frame:
Randomization to 24 weeks
Reported as:
Mean · Weeks
Time to First Administration of Flare Rescue Medication
WeeksTocilizumab+Prednisone (Tapering Dose)Tocilizumab+Prednisone (Constant Dose)
Time to First Administration of Flare Rescue Medication13.59 ± 6.778.76 ± 5.26
SecondaryNumber of Administrations of Flare Rescue Medication

Proportion of participants who received courses of RA flare rescue medication by number of courses received.

Time frame:
Randomization to 24 weeks
Reported as:
Number · Percentage of Participants
Number of Administrations of Flare Rescue Medication
Percentage of ParticipantsTocilizumab+Prednisone (Tapering Dose)Tocilizumab+Prednisone (Constant Dose)
0 courses79.493.8
1 course15.33.9
2 courses4.61.6
3 courses00.8
>3 courses0.80
SecondaryCumulative Prednisone Exposure (Dose)

In Post-randomization prednisone arm, Cumulative dose = (number of capsules taken during week 1 to 4 \* 1 mg) + (3/4 \* number of capsules taken during week 5 to 8 \* 1 mg) + (1/2 \* number of capsules taken during week 9 to 12 \* 1 mg) + (1/4 \* number of capsules taken during week 13 to 16 \* 1 mg). In continued arm, cumulative dose = (1/4 \* number of capsule taken \* 5 mg). Cumulative prednisone dose is defined as cumulative blinded prednisone + cumulative flare rescue prednisone.

Time frame:
Randomization to 24 weeks
Reported as:
Mean · mg
Cumulative Prednisone Exposure (Dose)
mgTocilizumab+Prednisone (Tapering Dose)Tocilizumab+Prednisone (Constant Dose)
Cumulative blinded prednisone dose267.099 ± 40.048769.459 ± 175.882
Cumulative flare rescue prednisone dose98.519 ± 51.921121.875 ± 54.898
Cumulative prednisone dose287.405 ± 63.184777.136 ± 172.881
SecondaryPercentage of Participants Who Maintain LDA (DAS28 ESR Score <=3.2) or Remission (DAS28 ESR Score <2.6) and the Percentage of Participants Who Maintain the Baseline Disease Activity Level

The proportion of participants who maintained LDA and the proportion of participants who maintained the baseline disease activity level at Week 24. LDA was defined as DAS28 ESR score \<= 3.2. Remission was defined as DAS28 ESR score \<= 2.6. Participants who maintained the baseline activity was defined as DAS28-ESR at Week 24 \<= DAS28-ESR at baseline.

Time frame:
Randomization to Week 24
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Maintain LDA (DAS28 ESR Score <=3.2) or Remission (DAS28 ESR Score <2.6) and the Percentage of Participants Who Maintain the Baseline Disease Activity Level
Percentage of ParticipantsTocilizumab+Prednisone (Tapering Dose)Tocilizumab+Prednisone (Constant Dose)
LDA at baseline97.796.9
LDA at Week 2473.483.1
Baseline DAS28-ESR ≤ 2.678.676.6
Remission at Week 2461.281.6
Maintained baseline activity at Week 2436.654.7
SecondaryPercentage of Participants Who Permanently Discontinue Study Treatment Due to Insufficient Flare Control

Percentage of participants who permanently discontinue study treatment due to insufficient flare control

Time frame:
24 weeks
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Permanently Discontinue Study Treatment Due to Insufficient Flare Control
Percentage of ParticipantsTocilizumab+Prednisone (Tapering Dose)Tocilizumab+Prednisone (Constant Dose)
Percentage of Participants Who Permanently Discontinue Study Treatment Due to Insufficient Flare Control00.8
SecondaryChanges From Baseline in American College of Rheumatology (ACR) Core Set Components at Week 24: Swollen 66 Joint Counts

Count of swollen joints based upon 66 assessed joints.

Time frame:
Baseline to Week 24
Reported as:
Mean · Swollen joints
Changes From Baseline in American College of Rheumatology (ACR) Core Set Components at Week 24: Swollen 66 Joint Counts
Swollen jointsTocilizumab+Prednisone (Tapering Dose)Tocilizumab+Prednisone (Constant Dose)
Changes From Baseline in American College of Rheumatology (ACR) Core Set Components at Week 24: Swollen 66 Joint Counts0.129 ± 6.687-0.107 ± 1.618
SecondaryChanges From Baseline in American College of Rheumatology (ACR) Core Set Components at Week 24: Tender 68 Joint Counts

Count of tender joints based on 68 assessed joints.

Time frame:
Baseline to Week 24
Reported as:
Mean · Tender joints
Changes From Baseline in American College of Rheumatology (ACR) Core Set Components at Week 24: Tender 68 Joint Counts
Tender jointsTocilizumab+Prednisone (Tapering Dose)Tocilizumab+Prednisone (Constant Dose)
Changes From Baseline in American College of Rheumatology (ACR) Core Set Components at Week 24: Tender 68 Joint Counts0.793 ± 7.764-0.330 ± 2.729
SecondaryChanges From Baseline in American College of Rheumatology (ACR) Core Set Components at Week 24: Patient's Assessment of Pain

The ACR patient's assessment of pain is scored on a visual analog scale (VAS) from 0 (no pain) to 100 mm (unbearable pain). A positive change in score indicates worsening, and a negative change indicates improvement.

Time frame:
Baseline to Week 24
Reported as:
Mean · mm
Changes From Baseline in American College of Rheumatology (ACR) Core Set Components at Week 24: Patient's Assessment of Pain
mmTocilizumab+Prednisone (Tapering Dose)Tocilizumab+Prednisone (Constant Dose)
Changes From Baseline in American College of Rheumatology (ACR) Core Set Components at Week 24: Patient's Assessment of Pain4.648 ± 24.315-8.010 ± 25.980
SecondaryChanges From Baseline in American College of Rheumatology (ACR) Core Set Components at Week 24: Patient's Global Assessment of Disease Activity

The ACR patient's global assessment of disease activity is scored on a visual analog scale (VAS) from 0 (symptom-free and no arthritis symptoms) to 100 mm (maximum arthritis disease activity). A positive change in score indicates worsening, and a negative change indicates improvement.

Time frame:
Baseline to Week 24
Reported as:
Mean · cm
Changes From Baseline in American College of Rheumatology (ACR) Core Set Components at Week 24: Patient's Global Assessment of Disease Activity
cmTocilizumab+Prednisone (Tapering Dose)Tocilizumab+Prednisone (Constant Dose)
Changes From Baseline in American College of Rheumatology (ACR) Core Set Components at Week 24: Patient's Global Assessment of Disease Activity0.280 ± 2.000-0.153 ± 1.506
SecondaryChanges From Baseline in American College of Rheumatology (ACR) Core Set Components at Week 24: Physician's Global Assessment of Disease Activity

The ACR physician's global assessment of disease activity is scored on a visual analog scale (VAS) from 0 (symptom-free and no arthritis symptoms) to 100 mm (maximum arthritis disease activity). A positive change in score indicates worsening, and a negative change indicates improvement.

Time frame:
Baseline to Week 24
Reported as:
Mean · cm
Changes From Baseline in American College of Rheumatology (ACR) Core Set Components at Week 24: Physician's Global Assessment of Disease Activity
cmTocilizumab+Prednisone (Tapering Dose)Tocilizumab+Prednisone (Constant Dose)
Changes From Baseline in American College of Rheumatology (ACR) Core Set Components at Week 24: Physician's Global Assessment of Disease Activity0.345 ± 1.463-0.248 ± 1.167
SecondaryChanges From Baseline in American College of Rheumatology (ACR) Core Set Components at Week 24: Health Assessment Questionnaire-Disability Index (HAQ-DI)

A measure of self-perceived disability containing 20 questions in eight categories and including additional section about aid from other people and devices needed to correct the disabilities. Scores range from 0 to 3, with higher scores indicating worse disability.

Time frame:
Baseline to Week 24
Reported as:
Mean · Score on a scale
Changes From Baseline in American College of Rheumatology (ACR) Core Set Components at Week 24: Health Assessment Questionnaire-Disability Index (HAQ-DI)
Score on a scaleTocilizumab+Prednisone (Tapering Dose)Tocilizumab+Prednisone (Constant Dose)
Changes From Baseline in American College of Rheumatology (ACR) Core Set Components at Week 24: Health Assessment Questionnaire-Disability Index (HAQ-DI)0.167 ± 0.486-0.087 ± 0.527
SecondaryChanges From Baseline in American College of Rheumatology (ACR) Core Set Components at Week 24: High Sensitivity C-Reactive Protein (hsCRP)

Change from baseline in the acute phase reactant hsCRP

Time frame:
Baseline to Week 24
Reported as:
Mean · mg/dL
Changes From Baseline in American College of Rheumatology (ACR) Core Set Components at Week 24: High Sensitivity C-Reactive Protein (hsCRP)
mg/dLTocilizumab+Prednisone (Tapering Dose)Tocilizumab+Prednisone (Constant Dose)
Changes From Baseline in American College of Rheumatology (ACR) Core Set Components at Week 24: High Sensitivity C-Reactive Protein (hsCRP)-0.135 ± 1.470-0.040 ± 0.277
SecondaryChanges From Baseline in American College of Rheumatology (ACR) Core Set Components at Week 24: Erythrocyte Sedimentation Rate (ESR)

Change from baseline in the acute phase reactant ESR

Time frame:
Baseline to Week 24
Reported as:
Mean · mm/hr
Changes From Baseline in American College of Rheumatology (ACR) Core Set Components at Week 24: Erythrocyte Sedimentation Rate (ESR)
mm/hrTocilizumab+Prednisone (Tapering Dose)Tocilizumab+Prednisone (Constant Dose)
Changes From Baseline in American College of Rheumatology (ACR) Core Set Components at Week 24: Erythrocyte Sedimentation Rate (ESR)1.517 ± 7.892-0.679 ± 5.433
SecondaryChanges From Baseline in Rheumatoid Arthritis Impact of Disease (RAID) Final Score

The RAID is a participant-completed questionnaire specific for RA consisting of a 0-10 rating for pain, functional disability, fatigue, sleep, physical well-being, emotional well-being and coping. Scores are weighted to produce a final numerical result. A positive change in score indicates worsening, and a negative change indicates improvement.

Time frame:
Baseline and Week 24
Reported as:
Mean · Score on a scale
Changes From Baseline in Rheumatoid Arthritis Impact of Disease (RAID) Final Score
Score on a scaleTocilizumab+Prednisone (Tapering Dose)Tocilizumab+Prednisone (Constant Dose)
Changes From Baseline in Rheumatoid Arthritis Impact of Disease (RAID) Final Score0.469 ± 2.109-0.220 ± 1.940
SecondaryChanges From Baseline in Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI:SHP) Score

The WPAI:SHP is a 6-item questionnaire to measure performance impairment of work and regular daily activity and yields 4 types of scores: work time missed (absenteeism), impairment while working (presenteeism or reduced on-the-job effectiveness), overall work impairment (WI) (work productivity loss or absenteeism plus presenteeism) and activity impairment (daily activity impairment). Total score and each score range from 0 (not affected/no impairment) to 100 (completely affected/impaired). Higher scores indicate greater impairment and less productivity. A positive change in score indicates impairment, and a negative change indicates improvement.

Time frame:
Baseline and Week 24
Reported as:
Mean · Score on a scale
Changes From Baseline in Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI:SHP) Score
Score on a scaleTocilizumab+Prednisone (Tapering Dose)Tocilizumab+Prednisone (Constant Dose)
Percent work time missed due to problem4.535 ± 23.2830.572 ± 31.455
Percent impairment while working due to problem-0.851 ± 24.920-5.584 ± 23.343
Percent overall work impairment due to problem6.219 ± 29.223-6.191 ± 30.531
Percent activity impairment due to problem3.398 ± 23.786-4.190 ± 21.608
SecondaryChange From Baseline in Simplified Disease Activity Index (SDAI) at Week 24

The SDAI is the numerical sum of 5 outcome parameters: tender and swollen joint count based on a 28-joint assessment, patient and physician global assessment of disease activity according to 100-mm visual analog scale (VAS) and level of C-reactive protein in milligrams per deciliter (mg/dL, normal \<1 mg/dl). The total SDAI score range is 0-86, where higher scores indicate increased disease activity. A positive change in score indicates worsening, and a negative change indicates improvement.

Time frame:
Randomization to Week 24
Reported as:
Least squares mean · Score on a scale
Change From Baseline in Simplified Disease Activity Index (SDAI) at Week 24
Score on a scaleTocilizumab+Prednisone (Tapering Dose)Tocilizumab+Prednisone (Constant Dose)
Change From Baseline in Simplified Disease Activity Index (SDAI) at Week 242.511 (1.296 to 3.727)0.248 (-0.994 to 1.489)
Statistical analysis
  • Tocilizumab+Prednisone (Tapering Dose) vs Tocilizumab+Prednisone (Constant Dose) · ANCOVA · p = 0.009 · Least square means: 2.264 · 95% CI 0.574 to 3.953

Adverse events

Collected over Randomization to Week 28. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tocilizumab+Prednisone (Tapering Dose)0/131 (0%)7/131 (5.3%)46/131 (35.1%)
Tocilizumab+Prednisone (Constant Dose)0/128 (0%)4/128 (3.1%)21/128 (16.4%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventTocilizumab+Prednisone (Tapering Dose)Tocilizumab+Prednisone (Constant Dose)
PNEUMONIAInfections and infestations1/1311/128
CELLULITIS GANGRENOUSInfections and infestations0/1311/128
SCIATICANervous system disorders0/1311/128
DRUG HYPERSENSITIVITYImmune system disorders0/1311/128
PSYCHOTIC DISORDERPsychiatric disorders0/1311/128
ASTHMARespiratory, thoracic and mediastinal disorders0/1311/128
SPINAL COLUMN STENOSISMusculoskeletal and connective tissue disorders1/1310/128
OSTEOARTHRITISMusculoskeletal and connective tissue disorders1/1310/128
NEUTROPENIABlood and lymphatic system disorders1/1310/128
ATRIAL FIBRILLATIONCardiac disorders1/1310/128
Most frequent other events
Most frequent other events
EventTocilizumab+Prednisone (Tapering Dose)Tocilizumab+Prednisone (Constant Dose)
NASOPHARYNGITISInfections and infestations13/1319/128
ALANINE AMINOTRANSFERASE INCREASEDInvestigations9/1313/128
ASPARTATE AMINOTRANSFERASE INCREASEDInvestigations9/1312/128
ARTHRALGIAMusculoskeletal and connective tissue disorders8/1312/128
DIARRHOEAGastrointestinal disorders7/1315/128

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Tocilizumab+Prednisone (Tapering Dose)Tocilizumab+Prednisone (Constant Dose)Total
Mean54.8 ± 14.054.0 ± 12.854.4 ± 13.4
Sex: Female, Male
Sex: Female, Male(Participants)Tocilizumab+Prednisone (Tapering Dose)Tocilizumab+Prednisone (Constant Dose)Total
Female10397200
Male283159
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Tocilizumab+Prednisone (Tapering Dose)Tocilizumab+Prednisone (Constant Dose)Total
Hispanic or Latino101
Not Hispanic or Latino120114234
Unknown or Not Reported101424
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Tocilizumab+Prednisone (Tapering Dose)Tocilizumab+Prednisone (Constant Dose)Total
American Indian or Alaska Native101
Asian123
Native Hawaiian or Other Pacific Islander033
Black or African American000
White129123252
More than one race000
Unknown or Not Reported000
08

Study locations

39 sites
  • Hopital Pellegrin; Rhumatologie
    Bordeaux, 33076, France
  • Hopital de La Source
    Orleans, 45067, France
  • Hopital Cochin; Rhumatologie B
    Paris, 75679, France
  • Hopital Hautepierre; Rhumatologie
    Strasbourg, 67098, France
  • Hopital Purpan; Rhumatologie
    Toulouse, 31059, France
  • Praxis Dr. med. Reiner Kurthen
    Aachen, 52064, Germany
  • Asklepios Kllinikum Bad Abbach; Klinik für Rheumatologie und Klinische Immunologie
    Bad Abbach, 93077, Germany
  • Rheumatologische Gemeinschaftspraxis Grafschaft, Dr. med. Dorothea Pick, Dr. med. Christopher Amberg
    Bad Neuenahr-Ahrweiler, 53474, Germany
  • Charité Campus Mitte, Med.Klinik, Rheumatologie und Klinische Immunologie
    Berlin, 10117, Germany
  • SchlossPark-Klinik Berlin; Int. Med. II, Rheum. Osteo
    Berlin, 14059, Germany
  • Rheumatologisches MVZ Dresden GmbH, Dres. Holger Schwenke, Reiner Schwenke, Annekatrin Georgi
    Dresden, 01109, Germany
  • MVZ Ambulantes Rheumazentrum
    Erfurt, 99096, Germany
  • Dres. Florian Schuch, Ruediger de la Camp, Martin Hammerschmidt u.w.
    Erlangen, 91056, Germany
  • Universitätsklinikum Hamburg-Eppendorf Zentrum f.Innere Medizin Med.Klinik III
    Hamburg, 20246, Germany
  • Praxis Dr.med. Maria Höhle
    Hamburg, 22147, Germany
  • Rheumapraxis PD Dr.med. Bernhard Heilig
    Heidelberg, 69120, Germany
  • Klinik der Uni zu Köln; Klinik für Innere Medizin
    Köln, 50924, Germany
  • Rheumatologische Facharztpraxis Maren Sieburg
    Magdeburg, 39104, Germany
  • SMO.MD GmbH, Zentrum für klinische Studien
    Magdeburg, 39120, Germany
  • Praxiszentrum St. Bonifatius
    Muenchen, 81541, Germany
  • Klinikum der Universitat Munchen; Bereich Pettenkoferstr; Rheumaeinheit der medizinischen Klinik IV
    München, 80336, Germany
  • Rheumapraxis an der Hase
    Osnabrück, 49074, Germany
  • Rheumazentrum Ratingen - Studienambulanz
    Ratingen, 40878, Germany
  • Rheumatologische Schwerpunktpraxis am Feuersee
    Stuttgart, 70178, Germany
  • Universitätsklinikum Würzburg; Medizinische Klinik und Poliklinik II; Rheumatologie/Immunologie
    Würzburg, 97080, Germany
  • Arcispedale Santa Maria Nuova; Reumatologia
    Reggio Emilia, Emilia-Romagna 42100, Italy
  • Irccs Policlinico San Matteo; Reumatologia Adulti
    Pavia, Lombardia 27100, Italy
  • Ospedale Careggi Villa Monnatessa ; Sezione Di Reumatologia
    Firenze, Toscana 50139, Italy
  • FSBI Scientific Research Institute of Clinical and Experimental Lymphology of SB of RAMS
    Novosibirsk, 630117, Russian Federation
  • Perm Regional Clinical Hospital
    Perm, 614000, Russian Federation
  • SBEI of HPE "Northwestern State Medical University n.a. I.I.Mechnikov" of MoH of RF
    Saint-Petersburg, 195067, Russian Federation
  • Republican clinical hospital named after G.G. Kuvatov
    UFA, 450005, Russian Federation
  • City Clinical Hospital # 2
    Vladivostok, 690105, Russian Federation
  • Institute of Rheumatology
    Belgrade, 11000, Serbia
  • Military Medical Academy; Clinic of Rheumatology
    Belgrade, 11000, Serbia
  • Institute of Rheumatology and Cardiovascular Diseases; Rheumatology
    Niska Banja, 18205, Serbia
  • Clinical Center of Vojvodina
    Novi Sad, 21000, Serbia
  • Special hospital for rheumatic diseases Novi Sad
    Novi Sad, 21000, Serbia
  • Hopital Farhat Hached; Service Rhumatologie
    Sousse, 4000, Tunisia
09

References and documents

Publications

  • Burmester GR, Buttgereit F, Bernasconi C, Alvaro-Gracia JM, Castro N, Dougados M, Gabay C, van Laar JM, Nebesky JM, Pethoe-Schramm A, Salvarani C, Donath MY, John MR; SEMIRA collaborators. Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial. Lancet. 2020 Jul 25;396(10246):267-276. doi: 10.1016/S0140-6736(20)30636-X. PubMed 32711802 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2016 to primary completion in Feb 2018, 22 months.

Results were first posted in Jul 2019, 1 year 5 months after primary completion.

Of 25 industry-sponsored phase 4 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 26 months of starting (the median); a quarter within 16 and three quarters within 44. This study's 22 months is below that.

Counting every sponsor, half of 104 studies reached it within 42 months; a quarter within 25 and three quarters within 74.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 1, 2015
First posted
Oct 9, 2015
StartActual
Mar 29, 2016
Primary completionActual
Feb 9, 2018
CompletionActual
Feb 9, 2018
Results first posted
Jul 24, 2019
Last update
Nov 1, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 1, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02573012
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Oct 9, 2015
Start date
Mar 29, 2016
Primary completion
Feb 9, 2018
Completion
Feb 9, 2018
Results posted
Jul 24, 2019
Last update
Nov 1, 2019

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tocilizumab

Start the discussion